Antegenes
PrivateLast Round
Grant
Aug 2, 2022
Total Funding Raised
$2.91M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Antegenes operates in Healthcare & Life Sciences and is based in Tartu. Its latest recorded funding round was a Grant round in August 2022.
Antegenes is a health technology company that develops and provides polygenic risk score-based genetic tests for the personalized prevention and early detection of common cancers.
Sector
Healthcare & Life Sciences
Verticals
Precision Medicine, Biotechnology
Business Model
B2B2C
Customer Profile
Usage-Based SaaS, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Antegenes Comparables
Compare Antegenes with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| GENinCode PLC | 81% | |
| Allelica, Inc. | 80% | |
| Genetic Technologies Limited | 76% |
For institutional investors. Book with your work email.
Antegenes Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Aug 2, 2022 | ||||
| Grant | Aug 2, 2022 | ||||
| Seed | Aug 2, 2022 | ||||
| Seed | Nov 9, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Antegenes Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EIT Health | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 45% MoM, reaching 1.1K.
- May 19, 2026
Monthly visitors increased 53% MoM.
For institutional investors. Book with your work email.
Antegenes Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Antegenes's valuation, stock price, and market status.
Is Antegenes a public or private company?
Antegenes is a private company.
What is the current stock price of Antegenes?
Antegenes is a private company, so its shares have no public market price. Caplight tracks Antegenes's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Antegenes worth (valuation)?
Valuation information for Antegenes is not publicly available.
Can I buy Antegenes stock?
Antegenes shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Antegenes's last funding round?
Antegenes's most recent funding round was Grant on August 2, 2022.
Who are the main investors in Antegenes?
Key investors in Antegenes include EIT Health.
Will Antegenes IPO soon?
No public IPO plans have been announced for Antegenes.
How can I track Antegenes secondary market activity?
Caplight tracks bids, offers, and trades in Antegenes's shares on secondary markets.